A Randomised, Open-Label, Single-Dose, Single-Centre, Crossover Study in Healthy Subjects to Assess the Relative Bioavailability of Symbicort pMDI 160/4.5µg Administered With a Spacer (With and Without Charcoal) and Symbicort pMDI 160/4.5µg Administered Without a Spacer (With and Without Charcoal).

Trial Profile

A Randomised, Open-Label, Single-Dose, Single-Centre, Crossover Study in Healthy Subjects to Assess the Relative Bioavailability of Symbicort pMDI 160/4.5µg Administered With a Spacer (With and Without Charcoal) and Symbicort pMDI 160/4.5µg Administered Without a Spacer (With and Without Charcoal).

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Apr 2017

At a glance

  • Drugs Budesonide/formoterol (Primary)
  • Indications Asthma; Chronic obstructive pulmonary disease
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 31 Mar 2017 Status changed from recruiting to completed.
    • 30 Nov 2016 Planned End Date changed from 1 Feb 2017 to 1 Mar 2017.
    • 30 Nov 2016 Planned primary completion date changed from 1 Feb 2017 to 1 Mar 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top